Cause:

Chronic inflammation of the prostate gland (prostate gland) in men can develop from acute bacterial prostatitis that has not completely healed (chronic bacterial prostatitis) or it can develop primarily on the basis of causes that have not yet been clearly diagnosed (chronic abacterial prostatitis). Current research shows that CAP is most likely triggered and maintained on the basis of autoimmune processes, whereby there is an increased release of messenger substances from tissue and inflammatory cells that permanently stimulate the inflammatory process in the prostate.

In the course of this permanent inflammation, painful scarring and calcium deposits increasingly occur within the prostate and, as a result, painful tension of the pelvic floor muscles. In addition, chronic prostatitis increases the likelihood of prostate cancer.

Symptoms:

• Pain or discomfort in the prostate, perineal and inguinal areas
• Pain or discomfort in the scrotum, testicles and anus area
• Painful bowel movement
• Discomfort during urination (frequent, difficult, painful urination, weakening of the urinary stream)
• Potency

New therapeutic approach with CGF

Under sonographic control, the CGF concentrate is injected into the inflammatory scarred tissue of the prostate (= prostate gland) immediately after production via multiple targeted punctures under a brief general anesthetic. The chronic inflammatory process can usually be slowed down or even stopped with the help of CGF.

The micro-scarring in the organ can disappear, the inflammatory reaction subsides, and  lasting relief of the symptoms can often be achieved after a few weeks. If necessary, this treatment can also be applied several times without any problems. Side effects such as allergies or intolerances of any kind are not observed with this procedure, since only the body's own substances are used for therapy.

Cause:

Urinary incontinence is the involuntary, uncontrolled release of urine. Urinary incontinence is a widespread condition that primarily affects women in middle and old age, but also men. Due to increasing life expectancy, in which many people want to continue to live an active life in old age, this condition and its treatment are becoming more and more important, both medically and socially. Medically, a distinction is made between stress and urge incontinence of the urinary bladder. Stress incontinence is an involuntary loss of urine without a noticeable urge to urinate during physical exertion such as lifting, carrying, sneezing and coughing. Urge incontinence, on the other hand, is a bladder retention disorder. In this case, the bladder muscle contracts involuntarily even when the bladder is only slightly full. The urge to urinate, which cannot be suppressed (imperative), leads to involuntary loss of urine.

Causes of urinary incontinence can be degenerative connective tissue and/or nerve damage, muscle weaknesses of the pelvic floor as well as sphincter injuries or inflammatory urinary bladder processes. These causes occur individually or multifactorially, for example in the following cases:

• Pregnancy/pelvic floor injury during birth
• Injuries or operations in the pelvic floor area
• Menopause of the woman (climacteric)
• Sphincter injury (after prostate surgery, accident, radiation)
• Urinary tract infections
• Urinary bladder stones
• Urinary bladder tumor
• Foreign body in the bladder
• Nervous diseases for example multiple sclerosis, tabes dorsalis, neuromyelitis, diabetes mellitus
• Spinal cord injuries
• Diseases in the brain stem area
• Aging processes
• Idiopathic processes (processes with unknown cause)

Symptoms:

• Loss of urine typically due to increased pressure in the abdomen (coughing, physical exertion)
• Involuntary, unwanted and uncontrolled loss of urine

New therapeutic approach with CGF and stem cells

Omnipotent stem cells - obtained from the patient's own fat tissue - are first mixed with concentrated growth factors (CGF) components from the patient's blood and processed into a collagen gel. This gel is applied on an outpatient basis under general anesthesia directly into and circularly around the functionally damaged sphincter muscle in the perisphincteric mucous membrane and muscle tissue using ultrasound and endoscopy.

The collagen gel has a “bulking effect” (or “cushion effect”). This seals the incontinent urinary outlet. The stem cells contained in the sphincter tissue can then differentiate into muscle cells or stimulate the formation of further muscle cells, which in turn increases the regeneration of the contraction and thus the continence ability of the insufficient (functionally weakened) sphincter muscle again. Depending on the healing process, the treatment can be repeated at any time.

Cause:

Overall, IC is a very rare disease in women. Interstitial cystitis (IC) is a chronic, autoimmune-triggered urinary bladder inflammation of unknown cause without evidence of bacteria. In addition to a change in the permeability of the bladder mucosa as a result of a disturbed mucosal layer of the bladder, cell-damaging substances contained in the urine and hidden infections are discussed as possible causes of IC.

A targeted, long-lasting therapy regime is not yet known. Patients with IC often also suffer from multiple allergies, fibromyalgia and chronic inflammatory bowel diseases.

Symptoms:

• pronounced pain in the area of the urinary bladder and in the pelvic region
• urge to urinate that cannot be suppressed (urge incontinence)
• low urine volume during urination due to shrinking bladder
• increased discomfort induced by coffee, citrus fruits, psychological stress
• blood in the urine (painful hematuria)

New therapeutic approach with CGF / stem cells

In the case of interstitial cystitis, an endoscopic quaddling (special injection technique) of the bladder mucosa with CGF (endogenous growth factors), possibly combined with stem cells, is carried out in an outpatient therapy session under general anesthesia in order to promote mucosal regeneration as a result of an inflammation inhibition within the bladder mucosa and therefore prevent further painful shrinkage of the bladder.

Cause:

The main cause of potency disorders in men is the lack of arterial blood flow to the erectile tissue as a result of vascular diseases or nerve disorders. Younger patients in particular with potency disorders, on the other hand, psychological disorders predominate. On average, 25% of all men suffer from erectile dysfunction.

Diseases that often lead to erectile dysfunction are:

• Arteriosclerosis
• Diabetes mellitus
• Prostate surgery for prostate cancer
• Vasculitides (vascular inflammations)
• Smoking
• Alcohol
• Obesity
• Lack of exercise
• Alzheimer's disease
• Parkinson's disease
• Multiple sclerosis
• Hypertension
• Fatty liver
• Dyslipidemia

Symptoms:

Decreased or absent member stiffness (erection) with limited ability to perform sexual intercourse.

New therapeutic approach with CGF

The tissue-regenerative properties of CGF are based, among other things, on the fact that angiogenesis, i.e. blood flow as a result of the formation of new vessels, is increased by CGF in the tissue and this can lead to an improvement in the blood supply to the erectile tissue, which in turn is reflected in a better oxygen supply in the erectile tissue.

This increased oxygen saturation results in improved functionality of the corpus cavernosum tissue and therefore improved stiffness of the penis. CGF is applied to the corpus cavernosum on an outpatient basis in our practice 4 - 8 times every 1 - 2 weeks and can be repeated as often as desired depending on the effect.

Kraurosis vulvae in medicine describes a peculiar shrinkage of the female vaginal entrance with increasing loss of elasticity of the outer and inner vaginal mucosa.

Microscopically, a chronic inflammation of the vaginal connective tissue with a tendency to scarring and oedema formation of the vaginal mucosa can be observed. One of the causes is the estrogen deficiency that occurs during menopause.

Symptoms:

• Mucosal fibrosis (proliferation of tissue) in the female genital tract
• Vaginal itching
• Vaginal/mucosal bleeding
• Urinary tract infections
• Irritable bladder
• Dyspareunia (pain during sexual intercourse)
• Anorgasmia

New therapeutic approach with CGF

The regenerative properties of CGF on the vaginal tissue are based, among other things, on the fact that angiogenesis, i.e. blood flow, is increased as a result of new blood vessel formation in the tissue stimulated by CGF, resulting in regeneration of the vaginal mucosa. In this outpatient treatment, CGF is injected circularly into the introitus and vaginal mucosa under general anesthesia. Depending on the effect, the treatment can be repeated.

Cause:

In urethral stenosis, the diameter of the urethra narrows (stenosis), usually as a result of scarring of the urethral wall, which can lead to considerable discomfort when urinating, and even to acute urinary retention.

As a result of insufficient emptying of the urinary bladder, urinary tract infections often occur which, in serious cases, can also affect the kidneys as part of an inflammation of the renal pelvis. Causes of urethral obstruction can include:

• Iatrogenic after urethral slit/ bladder catheterization
• Permanent catheter
• Radiation
• Scarring after injury to the urethra
• Infection (urethritis)

Symptoms:

• Urinary bladder voiding disorders
• Residual urine
• Painful urination
• Urinary tract infections

New therapeutic approach with CGF/stem cells

The regenerative properties of CGF on damaged tissue, also used in plastic surgery for the correction of scars, are based primarily on an anti-inflammatory and thus antifibrotic (scar-inhibiting) effect, in addition to a blood circulation-increasing CGF effect.

This effect can be supported in individual cases by an additional stem cell application. In this outpatient treatment, CGF is applied endoscopically into the urethral mucosa under general anesthesia after slitting and dilating the urethra in a circular fashion around the stenosis (narrowing). CGF has the additional advantage of significantly reducing the risk of recurrence after urethral slitting. Depending on the effect, therapy can be repeated.

Cause:

Narrowing of the bladder outlet (bladder neck sclerosis) presents as scarring and constriction of the bladder outlet, which can usually occur as a result of injury, inflammation, after radiation of a tumorous disease in the pelvic region or after radical prostate removal for prostate cancer.

Symptoms:

• Urinary bladder voiding disorders
• Residual urine
• Painful urination
• Urinary tract infections

New therapeutic approach with CGF - stem cell refeeding (Lipogems)

The regenerative properties of CGF on damaged tissue, also used in plastic surgery for the correction of scars, are based primarily on an anti-inflammatory and thus antifibrotic (scar-inhibiting) effect, in addition to a blood circulation-increasing CGF effect.

Additionally administered stem cell concentrates (Lipogems) support the healing process and reduce the risk of bladder neck sclerosis recurrence (relapse), which are often quite high after conventional endoscopic slitting or bougienage.

In this outpatient treatment, the CGF stem cell mixture is applied endoscopically under general anesthesia into the bladder neck mucosa and submucosa in a circular fashion around the bladder neck after slitting and dilating the bladder neck sclerosis. Depending on the healing process, treatment can be repeated.